Your browser doesn't support javascript.
loading
Secondary Prevention Therapies in Real-World Patients with Myocardial Infarction: Eligibility Based on Randomized Trials Supporting European and American Guidelines.
Mas-Llado, Caterina; Rossello, Xavier; González-Del-Hoyo, Maribel; Pocock, Stuart; de Werf, Frans Van; Chin, Chee Tang; Danchin, Nicolas; Lee, Stephen W-L; Medina, Jesús; Huo, Yong; Bueno, Héctor.
Afiliación
  • Mas-Llado C; Cardiology Department, Hospital de Manacor, Spain; Health Research Institute of the Balearic Islands, Palma, Spain; Facultad de Medicina, Universitat de les Illes Balears, Palma, Spain.
  • Rossello X; Health Research Institute of the Balearic Islands, Palma, Spain; Facultad de Medicina, Universitat de les Illes Balears, Palma, Spain; Cardiology Department, Health Research Institute of the Balearic Islands, Hospital Universitari Son Espases, Palma, Spain; Centro Nacional de Investigaciones Cardiov
  • González-Del-Hoyo M; Health Research Institute of the Balearic Islands, Palma, Spain.
  • Pocock S; London School of Hygiene and Tropical Medicine, UK.
  • de Werf FV; Department of Cardiovascular Sciences, University of Leuven, Belgium.
  • Chin CT; National Heart Centre Singapore.
  • Danchin N; Hôpital Européen Georges Pompidou & René Descartes University, France.
  • Lee SW; Queen Mary Hospital, China.
  • Medina J; BioPharmaceuticals Medical, AstraZeneca, Spain.
  • Huo Y; Beijing University First Hospital, China.
  • Bueno H; Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain; Cardiology Department, Hospital Universitario 12 de Octubre, and Instituto de Investigación i+12, Madrid, Spain; Facultad de Medicina, Universidad Complutense de Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedade
Am J Med ; 137(2): 137-146.e10, 2024 Feb.
Article en En | MEDLINE | ID: mdl-37838236
ABSTRACT

OBJECTIVE:

We aimed to evaluate the applicability of the eligibility criteria of randomized controlled trials (RCTs) cited in guideline recommendations in a real-world cohort of patients receiving secondary prevention after acute myocardial infarction from the EPICOR registries.

METHODS:

Recommendations provided by American and European guidelines for acute myocardial infarction were classified into general (applying to all patients) and specific (applying to patients with left ventricular dysfunction or heart failure). Randomized controlled trials cited in these recommendations were selected, and their entry criteria were applied to our international cohort of 18,117 patients.

RESULTS:

There were 91.5% patients eligible for beta blockers (84.6% for general, and 5.9% for specific recommendations), 97.7% eligible for renin-angiotensin system inhibitor (angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers [ACEI/ARB]) recommendations (69.9% for general, 27.9% for specific) and 4.1% eligible for mineralocorticoid receptor antagonists (only specific recommendations). The percentages of patients with eligibility criteria who were discharged with a prescription of the recommended therapies were 80%-85% for beta blockers, 70%-75% for ACEI/ARB, and 29% for mineralocorticoid receptor antagonists. There were large regional variations in the percentage of eligible patients and in those receiving the medications (eg, 95% in Northern Europe and 57% in Southeast Asia for beta blockers).

CONCLUSION:

Most real-world acute myocardial infarction patients are eligible for secondary prevention therapy in both general and specific guideline recommendations, and the percentage of those on beta blockers and ACEI/ARB at hospital discharge is high. There are large regional variations in the proportion of patients receiving recommended therapies. Local targeted interventions are needed for quality improvement.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Antagonistas de Receptores de Mineralocorticoides / Infarto del Miocardio Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: Am J Med Año: 2024 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Antagonistas de Receptores de Mineralocorticoides / Infarto del Miocardio Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: Am J Med Año: 2024 Tipo del documento: Article País de afiliación: España